Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Natera, Inc.    NTRA

NATERA, INC.

(NTRA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/14/2021 01/15/2021 01/19/2021 01/20/2021 01/21/2021 Date
115.91(c) 120.16(c) 123.9(c) 123.38(c) 121.305 Last
876 887 1 051 250 744 416 1 085 177 321 970 Volume
+2.32% +3.67% +3.11% -0.42% -1.68% Change
More quotes
Financials (USD)
Sales 2020 385 M - -
Net income 2020 -204 M - -
Net cash position 2020 510 M - -
P/E ratio 2020 -48,6x
Yield 2020 -
Sales 2021 463 M - -
Net income 2021 -194 M - -
Net cash position 2021 408 M - -
P/E ratio 2021 -52,1x
Yield 2021 -
Capitalization 10 533 M 10 533 M -
EV / Sales 2020 26,0x
EV / Sales 2021 21,9x
Nbr of Employees 1 039
Free-Float 95,4%
More Financials
Company
Natera, Inc. is a diagnostics company. The Company is engaged in the discovery, development and commercialization of genetic testing services. It offers Panorama Non-Invasive Prenatal Test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Horizon Carrier Screening to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's... 
More about the company
Notations Surperformance© of Natera, Inc.
Trading Rating : Investor Rating :
More Ratings
All news about NATERA, INC.
01/20NATERA : Files Patent Infringement Suit Against Inivata
PR
01/07NATERA : JP Morgan Adjusts Price Target for Natera to $110 From $95, Maintains O..
MT
01/05NATERA : to Webcast Live Presentation at the 39th Annual J.P. Morgan Healthcare ..
PR
01/04NATERA : Craig Hallum Adjusts Natera PT to $118 From $92, Maintains Buy Rating
MT
2020NATERA : Second Largest Commercial Insurer Covers Non-Invasive Prenatal Testing ..
PU
2020NATERA : Largest U.S. Health Plan Now Covers Non-Invasive Prenatal Testing (NIPT..
PU
2020NATERA : Says US Patent Office Upholds Validity of Patent Covering DNA Analysis ..
MT
2020NATERA : U.S. Patent Office Upholds Validity of Natera's Early Priority Date '59..
PR
2020NATERA : New Signatera™ Data to be Presented at the 2020 ESMO IO Congress ..
PR
2020NATERA : to Present New Immunotherapy Monitoring Data at SABCS 2020
PR
2020BTIG Adjusts Natera's Price Target to Street-High $105 From $95, Reiterates B..
MT
2020Natera Reports Prenatal Testing Coverage For All Pregnancies By Largest US He..
MT
2020NATERA : New Publication from I-SPY 2 Trial Highlights Signatera's Ability to Pr..
PR
2020INSIDER TRENDS : Natera Insider Exercises Options in Face of 90-Day Selling Tren..
MT
2020NATERA, INC. : Change in Directors or Principal Officers, Financial Statements a..
AQ
More news
News in other languages on NATERA, INC.

- No features available -

More news
Analyst Recommendations on NATERA, INC.
More recommendations
Chart NATERA, INC.
Duration : Period :
Natera, Inc. Technical Analysis Chart | NTRA | US6323071042 | MarketScreener
Technical analysis trends NATERA, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Average target price 118,11 $
Last Close Price 123,38 $
Spread / Highest target 13,5%
Spread / Average Target -4,27%
Spread / Lowest Target -29,5%
EPS Revisions
Managers and Directors
NameTitle
Stephen Chapman President, Chief Executive Officer & Director
Matthew Rabinowitz Executive Chairman
Robert A. Schueren Chief Operating Officer
Michael Burkes Brophy Chief Financial Officer
Jonathan Sheena Director & Chief Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
NATERA, INC.23.98%10 533
10X GENOMICS, INC.27.85%19 481
BIOMÉRIEUX4.16%17 205
DIASORIN S.P.A.0.59%11 303
AUTOBIO DIAGNOSTICS CO., LTD.-3.56%9 766
GUANGZHOU WONDFO BIOTECH CO.,LTD0.94%4 773